Page last updated: 2024-10-15

dipropylenetriamine-nonoate

Cross-References

ID SourceID
PubMed CID135453291
SCHEMBL ID4785299
SCHEMBL ID2520293
MeSH IDM0422129

Synonyms (16)

Synonym
dipropylenetriamine nonoate
n-[bis(3-aminopropyl)amino]-n-hydroxynitrous amide
146724-95-0
dpta/no
1-propanamine, 3,3'-(2-hydroxy-2-nitrosohydrazinylidene)bis
(z)-1-(n-(3-aminopropyl)-n-(3-ammoniopropyl)amino)-diazen-1-ium-1,2-diolate
dipropylenetriamine-nonoate
dpta nonoate
SCHEMBL4785299
SCHEMBL2520293
dipropylenetriaminenonoate
DTXSID20163464
J-008254
1-propanamine, 3,3'-(2-hydroxy-2-nitrosohydrazinylidene)bis-
(z)-[bis(3-aminopropyl)amino]-hydroxyimino-oxidoazanium
AKOS040755376

Bioavailability

ExcerptReference
" Here we have tested this high NO bioavailability hypothesis in the setting of experimental cerebral malaria (ECM), but find instead that low NO bioavailability contributes to the genesis of ECM."( Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria.
Contreras, R; Frangos, JA; Gramaglia, I; Intaglietta, M; Meays, D; Nolan, JP; Sobolewski, P; van der Heyde, HC, 2006
)
" In the Plasmodium berghei ANKA (PbA) murine model, CM pathogenesis is associated with low nitric oxide (NO) bioavailability and brain microcirculatory complications, with a marked decrease in cerebral blood flow, vasoconstriction, vascular plugging by adherent cells, and hemorrhages."( Nitric oxide protection against murine cerebral malaria is associated with improved cerebral microcirculatory physiology.
Cabrales, P; Carvalho, LJ; Frangos, JA; Meays, D; Zanini, GM, 2011
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's18 (81.82)29.6817
2010's4 (18.18)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.17%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]